Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.4800 (-3.01%) ($5.4000 - $5.8700) on Tue. Nov. 20, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.58% (three month average) | RSI | 43 | Latest Price | $5.4800(-3.01%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2% a day on average for past five trading days. | Weekly Trend | ADAP declines -9.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(16%) GDXJ(11%) JETS(11%) ICLN(9%) SHY(9%) | Factors Impacting ADAP price | ADAP will decline at least -2.79% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.79% (StdDev 5.58%) | Hourly BBV | 0 () | Intraday Trend | -1.3% | | | |
|
1 - 5 Day Possible Target | $-9.58(-274.82%) | Resistance Level | $6.21 | 5 Day Moving Average | $5.54(-1.08%) | 10 Day Moving Average | $5.93(-7.59%) | 20 Day Moving Average | $6.21(-11.76%) | To recent high | -61.3% | To recent low | 0.9% | Market Cap | $847m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |